Cocrystal Pharma (COCP)
(Delayed Data from NSDQ)
$1.56 USD
+0.05 (2.98%)
Updated Apr 26, 2024 03:57 PM ET
After-Market: $1.55 -0.01 (-0.32%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Cocrystal Pharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 2 | 7 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 2 | 7 |
Selling & Adminstrative & Depr. & Amort Expenses | 19 | 39 | 14 | 12 | 55 |
Income After Depreciation & Amortization | -19 | -39 | -14 | -10 | -48 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | -1 | 0 | 0 | 0 | 0 |
Pretax Income | -18 | -39 | -14 | -10 | -48 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -18 | -39 | -14 | -10 | -48 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -18 | -39 | -14 | -10 | -48 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -20 | -19 | -14 | -9 | -2 |
Depreciation & Amortization (Cash Flow) | -1 | 19 | 0 | 0 | 46 |
Income After Depreciation & Amortization | -19 | -39 | -14 | -10 | -48 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 9.65 | 8.14 | 7.36 | 4.60 | 2.65 |
Diluted EPS Before Non-Recurring Items | -1.87 | -2.23 | -1.92 | -2.04 | -0.72 |
Diluted Net EPS (GAAP) | -1.87 | -4.77 | -1.92 | -2.04 | -18.13 |
Fiscal Year end for Cocrystal Pharma, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 4.67 | 4.44 | 4.34 | 5.11 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -4.67 | -4.44 | -4.34 | -5.11 |
Non-Operating Income | NA | 0.02 | -0.04 | 0.17 | -0.08 |
Interest Expense | NA | -0.32 | -0.32 | 0.00 | 0.00 |
Pretax Income | NA | -4.46 | -4.17 | -4.17 | -5.19 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -4.46 | -4.17 | -4.17 | -5.19 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -4.46 | -4.17 | -4.17 | -5.19 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 10.15 | 10.15 | 10.07 | 8.14 |
Diluted EPS Before Non-Recurring Items | -99,999.00 | -0.44 | -0.41 | -0.50 | -0.64 |
Diluted Net EPS (GAAP) | -99,999.00 | -0.41 | -0.41 | -0.41 | -0.64 |